Get started
BIOMARIN PHAR. DL-,001BIOMARIN PHAR. DL-,001BIOMARIN PHAR. DL-,001

BIOMARIN PHAR. DL-,001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals Bonds

BM8 chart


Full chart

BM8 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪11.67 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
39.96
Basic EPS (TTM)
1.53 EUR
Net income (FY)
‪151.89 M‬ EUR
Revenue (FY)
‪2.19 B‬ EUR
Shares float
‪188.17 M‬
Beta (1Y)
0.29

About BioMarin Pharmaceutical Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Hardy
Website
biomarin.com
Headquarters
San Rafael
Founded
1997
FIGI
BBG000DB0RR1
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BM8 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BM8 highest yielding bonds


BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027
Yield to maturity
3.74%
Maturity date
May 15, 2027

Explore more bonds 

Sparks


Curated watchlists where BM8 is featured.

See all sparks 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on DUS exchange BIOMARIN PHAR. DL-,001 stocks are traded under the ticker BM8.
We've gathered analysts' opinions on BIOMARIN PHAR. DL-,001 future price: according to them, BM8 price has a max estimate of 117.22 EUR and a min estimate of 60.00 EUR. Watch BM8 chart and read a more detailed BIOMARIN PHAR. DL-,001 stock forecast: see what analysts think of BIOMARIN PHAR. DL-,001 and suggest that you do with its stocks.
BM8 reached its all-time high on Aug 5, 2015 with the price of 131.03 EUR, and its all-time low was 57.42 EUR and was reached on Feb 10, 2016. View more price dynamics on BM8 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track BIOMARIN PHAR. DL-,001 financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHAR. DL-,001 is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
BM8 earnings for the last quarter are 0.49 EUR per share, whereas the estimation was 0.48 EUR resulting in a 3.59% surprise. The estimated earnings for the next quarter are 0.51 EUR per share. See more details about BIOMARIN PHAR. DL-,001 earnings.
BIOMARIN PHAR. DL-,001 revenue for the last quarter amounts to ‪669.78 M‬ EUR, despite the estimated figure of ‪631.78 M‬ EUR. In the next quarter, revenue is expected to reach ‪655.84 M‬ EUR.
BM8 net income for the last quarter is ‪95.27 M‬ EUR, while the quarter before that showed ‪100.06 M‬ EUR of net income which accounts for −4.78% change. Track more BIOMARIN PHAR. DL-,001 financial stats to get the full picture.
No, BM8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has ‪3.40 K‬ employees. See our rating of the largest employees — is BIOMARIN PHAR. DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHAR. DL-,001 EBITDA is ‪440.48 M‬ EUR, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHAR. DL-,001 financial statements.
Like other stocks, BM8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHAR. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.